Asgard Therapeutics Raises €30M in Series A Financing

Asgard Therapeutics

Asgard Therapeutics, a Lund, Sweden-based biotech company developing in vivo direct cell reprogramming for cancer immunotherapy, raised €30M in Series A funding.

The round was led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

The company intends to use the funds to support development of its lead program AT-108 to IND-readiness by 2026, expand and reinforce its research and development team, and accelerate new reprogramming modalities and delivery platforms to strengthen the pipeline. 

Led by CEO Cristiana Pires, Asgard Therapeutics is a preclinical stage biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. It aims to establish a pipeline of off-the shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need.

Commenting on the news, Cristiana Pires said: “Asgard’s technology overcomes challenges faced by traditional cell therapies, enabling the recreation of desired functional immune cells directly inside the patient’s body. We believe this breakthrough strategy will give rise to the next generation of cell therapies. This financing also follows a strong pre-clinical package providing PoC for AT-108. We would like to thank both new and existing investors for their support as we discover and develop innovative immunotherapies with breakthrough potential and look forward to progressing our lead program AT-108 to the clinic.”